Both atomoxetine (a selective norepinephrine transporter inhibitor) and guanfacine (a selective α2A adrenoceptor agonist) are approved for the treatment of ADHD as non-stimulant class medications in Japan [7,24]. The gene discussed is SLC6A2; the disease is attention deficit-hyperactivity disorder.